Abiopharma

🔍 Ancira Karen (Executive)

Company: MATTEL INC /DE/ (MAT)

Report Date: 2026-05-07

Detailed Transactions and Holdings:

• Acquired 7,573 shares of Common Stock (Direct)
  Date: 2026-05-07 | Code: M | equity_swap_involved: 0 | shares_owned_after: 18,293.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 2,718 shares of Common Stock at $15.0 per share (Direct)
  Date: 2026-05-07 | Code: F | equity_swap_involved: 0 | shares_owned_after: 15,575.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 7,573 shares of Restricted Stock Units (Derivative)
  Date: 2026-05-07 | Code: M | equity_swap_involved: 0 | shares_owned_after: 15,376.00 | transaction_form_type: 4 | Footnotes: F1, F1, F1

Footnotes:

• F1: As reported on a Form 4 dated May 7, 2025 and filed on May 9, 2025, the Reporting Person received a grant of 22,949 Restricted Stock Units ("RSUs" or "Units") on May 7, 2025. The RSUs vest as to (a) 33% of the Units granted on the first anniversary of the date of grant, (b) an additional 33% of the Units granted on the second anniversary of the date of grant, and (c) the remaining 34% of the Units granted on the third anniversary of the date of grant. On each vesting date, for each Unit vesting on such date, the Reporting Person will receive one share of Mattel, Inc. Common Stock, subject to tax withholding. On May 7, 2026, the first 33% of these RSUs vested, resulting in the issuance of 7,573 shares of Mattel, Inc. Common Stock.
• F2: Pursuant to the terms of the May 7, 2025 RSU grant, 2,718 shares of Mattel, Inc. Common Stock were automatically withheld at vesting to cover required tax withholding.